Assessment of Aflibercept Treatment Outcomes in Diabetic Macular Edema Using the Quick Contrast Sensitivity Function

Background: Diabetic macular edema (DME) is a leading cause of visual impairment among patients with diabetes. Aflibercept, a high-affinity vascular endothelial growth factor (VEGF) inhibitor, reduces macular edema and improves visual acuity. Best-corrected visual acuity (BCVA) primarily assesses high-contrast visual resolution, provides limited information about vision at lower contrast levels, and may therefore miss subtle functional changes in certain conditions. Contrast sensitivity, however, is crucial for daily tasks. The quick contrast sensitivity function (qCSF; Adaptive Sensory Technology, San Diego, CA, USA), a computer-based clinical tool, provides a more comprehensive evaluation of visual function and may therefore capture additional functional information. This exploratory pilot study investigated longitudinal changes in qCSF outcomes, compared with conventional visual acuity testing, during intravitreal aflibercept treatment in patients with DME. Materials and methods: This prospective, observational, non-randomized longitudinal study included 21 eyes from 15 patients with clinically significant DME. With a median of 18 prior anti-VEGF injections, participants received further aflibercept (Eylea®, 2 mg) injections and were followed for 26 weeks (visits at baseline and at four, 12, and 26 weeks). Visual function was assessed using BCVA with Early Treatment Diabetic Retinopathy Study charts, quick visual acuity (qVA), and qCSF, with the area under the logarithmic contrast sensitivity function (AULCSF) as the primary outcome and CSF acuity as a secondary outcome. Central subfield thickness (CST) on optical coherence tomography and National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) scores were also recorded. Statistical analyses were exploratory and used linear mixed-effects models accounting for repeated measurements and inter-eye correlation. Results: Median BCVA improved from 80 to 82 letters (+0.74 letters per injection, 95% CI 0.03 to 1.45, p = 0.045). The qVA threshold showed no significant change. Median AULCSF increased by 0.12 log units after the first injection, but this was not statistically significant (p = 0.12), and no significant change was detected at 26 weeks. The reduction in CST correlated significantly with improvements in BCVA (p = 0.002), qVA threshold (p = 0.011), and AULCSF (p = 0.001). NEI-VFQ-25 scores were associated with functional outcomes (BCVA: p = 0.006; CSF acuity: p = 0.027). Conclusions: In this small exploratory pilot study, qCSF showed a numerically larger early change than BCVA after aflibercept injection; however, this difference was not statistically significant, was not formally compared, and was not sustained at 26 weeks. The findings are hypothesis-generating and do not establish that qCSF is more sensitive than BCVA; qCSF appears promising as a complementary functional measure, but larger controlled studies are needed.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-17
DOI
https://doi.org/10.7759/cureus.119809
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Assessment of Aflibercept Treatment Outcomes in Diabetic Macular Edema Using the Quick Contrast Sensitivity Function

Nicolas Feltgen, Philipp Anders, Petra Rossouw, Marco Cattaneo et al.
1 links
Cureus
Retinal Diseases and Treatments
article

Assessment of Aflibercept Treatment Outcomes in Diabetic Macular Edema Using the Quick Contrast Sensitivity Function

Nicolas Feltgen, Philipp Anders, Petra Rossouw, Marco Cattaneo, Hanna Zuche, Josep Callizo, Chrysoula Gabranni
article en

Abstract

Background: Diabetic macular edema (DME) is a leading cause of visual impairment among patients with diabetes. Aflibercept, a high-affinity vascular endothelial growth factor (VEGF) inhibitor, reduces macular edema and improves visual acuity. Best-corrected visual acuity (BCVA) primarily assesses high-contrast visual resolution, provides limited information about vision at lower contrast levels, and may therefore miss subtle functional changes in certain conditions. Contrast sensitivity, however, is crucial for daily tasks. The quick contrast sensitivity function (qCSF; Adaptive Sensory Technology, San Diego, CA, USA), a computer-based clinical tool, provides a more comprehensive evaluation of visual function and may therefore capture additional functional information. This exploratory pilot study investigated longitudinal changes in qCSF outcomes, compared with conventional visual acuity testing, during intravitreal aflibercept treatment in patients with DME. Materials and methods: This prospective, observational, non-randomized longitudinal study included 21 eyes from 15 patients with clinically significant DME. With a median of 18 prior anti-VEGF injections, participants received further aflibercept (Eylea®, 2 mg) injections and were followed for 26 weeks (visits at baseline and at four, 12, and 26 weeks). Visual function was assessed using BCVA with Early Treatment Diabetic Retinopathy Study charts, quick visual acuity (qVA), and qCSF, with the area under the logarithmic contrast sensitivity function (AULCSF) as the primary outcome and CSF acuity as a secondary outcome. Central subfield thickness (CST) on optical coherence tomography and National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) scores were also recorded. Statistical analyses were exploratory and used linear mixed-effects models accounting for repeated measurements and inter-eye correlation. Results: Median BCVA improved from 80 to 82 letters (+0.74 letters per injection, 95% CI 0.03 to 1.45, p = 0.045). The qVA threshold showed no significant change. Median AULCSF increased by 0.12 log units after the first injection, but this was not statistically significant (p = 0.12), and no significant change was detected at 26 weeks. The reduction in CST correlated significantly with improvements in BCVA (p = 0.002), qVA threshold (p = 0.011), and AULCSF (p = 0.001). NEI-VFQ-25 scores were associated with functional outcomes (BCVA: p = 0.006; CSF acuity: p = 0.027). Conclusions: In this small exploratory pilot study, qCSF showed a numerically larger early change than BCVA after aflibercept injection; however, this difference was not statistically significant, was not formally compared, and was not sustained at 26 weeks. The findings are hypothesis-generating and do not establish that qCSF is more sensitive than BCVA; qCSF appears promising as a complementary functional measure, but larger controlled studies are needed.

Cureus
University of Basel (CH), University Hospital of Basel (CH), Kantonsspital Baselland (CH), Vista Klinik (CH), Institute of Molecular and Clinical Ophthalmology Basel (CH)
Good health and well-being
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon